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SUMMARY
A total of 755 highly active antiretroviral therapy (HAART)-naive HIV-infected patients were
enrolled at a government hospital in Thailand from 1 June 2000 to 15 October 2002. Census date
of survival was on 31 October 2004 or the date of HAART initiation. Of 700 (92.6%) patients
with complete data, the prevalence of hepatitis B virus (HBV) surface antigen and anti-hepatitis C
virus (HCV) antibody positivity was 11.9% and 3.3%, respectively. Eight (9.6%) HBV
co-infected patients did not have anti-HBV core antibody (anti-HBcAb). During 1166.7
person-years of observation (pyo), 258 (36.9%) patients died [22.1/100 pyo, 95% confidence
interval (CI) 16.7–27.8]. HBV and probably HCV co-infection was associated with a higher
mortality with adjusted hazard ratios (aHRs) of 1.81 (95% CI 1.30–2.53) and 1.90 (95% CI
0.98–3.69), respectively. Interestingly, HBV co-infection without anti-HBc Ab was strongly
associated with death (aHR 6.34, 95% CI 3.99–10.3). The influence of hepatitis co-infection
on the natural history of HAART-naive HIV patients requires greater attention.
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INTRODUCTION
In resource-limited countries, the prevalence of
chronic hepatitis B virus (HBV) and hepatitis C virus
(HCV) infection is often high [1], and populations
with a high prevalence of HBV and HCV usually
overlap with those seriously affected by HIV. In a
study from northern India, the reported prevalence of
HBV and HCV co-infection in HIV-infected patients
was 5.3% and 2.4%, respectively [2]. A study in
Tanzania reported 17.3% and 18.1% of HIV-infected
patients were co-infected with HBV and HCV, re-
spectively [3], and an earlier report from Thailand
showed that the prevalence of HBV infection was
8.7% and HCV infection 7.8% in HIV-infected
patients [4].
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Clinical Medicine, Institute of Tropical Medicine (NEKKEN),
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Accumulating evidence suggests that HIV co-
infection adversely affects the clinical course of
hepatitis. Increased HBV carriage rates, greater levels
of HBV viraemia, more rapid decline in HBV surface
antibody, increased reactivation episodes, and faster
progression to liver cirrhosis are all characteristic of
HIV/HBV co-infected patients [5, 6]. In HIV/HCV
co-infected patients, faster progression of fibrosis
resulting in decompensated cirrhosis have been shown
in previous studies [7, 8]. As patients on highly
active antiretroviral therapy (HAART) survive much
longer, liver failure is becoming the major cause of
death in patients with hepatitis co-infection [9].
Current International AIDS Society guidelines for
the management of HIV recommend that HIV/viral
hepatitis co-infected patients should start HAART,
the same as HIV mono-infected patients. Moreover,
initiation of HAART is recommended regardless of
CD4 cell count when treatment for HBV is considered
[10]. However, there is a big gap between the
recommendation of the guidelines and the real-life
situation in resource-limited countries. While access
to HAART has markedly increased, even in resource-
limited countries [11], overall HAART coverage
remains as low as 36% (95% CI 33–39%) [11] based
on 2010 WHO guidelines (treatment initiation at
CD4 cell count <350 cells/ml. Moreover, monitoring
(viral load testing and genotyping) and treatment
for hepatitis are not available due to the cost in
most resource-limited countries. Thus, we assume
that there are still large groups of patients with
HIV/chronic hepatitis co-infection who are not
receiving HAART in resource-limited countries. For
better management of these patients, it is important to
know the association between hepatitis co-infection
and the natural history of HIV infection.
The effect of viral hepatitis co-infection on HIV
progression and all-cause mortality before initiating
HAART remains uncertain. Most studies conducted
in the late 1990s and early 2000s did not include HIV
viral load in their analysis. Some studies presented a
more rapid progression to AIDS and reduced survival
in patients who have chronic HBV or HCV infection
[12–15] while others have shown conflicting results
[16–19]. In the majority of previous studies examining
HBV and HCV co-infection, the main transmission
mode of HIV in participants was homosexual inter-
course or injecting drug use (IDU) and none were
conducted with a substantial sample size in Asian or
African countries where the majority of HIV-infected
individuals with HBV vertical transmission reside.
The present study aims to evaluate the impact
of hepatitis co-infection on all-cause mortality in
HAART-naive HIV-infected individuals in northern
Thailand.
METHODS
Study site and population
To address the current research question, we re-
analysed our previously conducted natural history
cohort of HIV-infected patients in northern Thailand
[20, 21]. This patient cohort was assembled from
volunteers at the HIV centre of a government referral
hospital with about 800 beds situated in the centre of
Lampang province in upper northern Thailand. The
centre was established in October 1995 as an out-
patient clinic providing treatment, care and support
for HIV-infected patients. The recruitment of this
cohort was from 1 July 2000 to 15 October 2002 be-
fore the national antiretroviral treatment programme
was launched. All adult (aged >18 years) HIV-
infected individuals attending the HIV clinic who
were HAART-naive at the first visit were approached
by the research team and enrolled if written consent
were obtained. All participants were requested to
visit the clinic at least once every 3 months regardless
of the presence of clinical symptoms and were fol-
lowed up from the date of study enrolment until
15 October, 2004. This study was approved by the
Thai Government Ethics Committee in December
1999 and December 2005.
Data collection
Demographic (gender and age at enrolment) data and
medical history [HIV-related symptoms, history of
antiretroviral therapy (ART) and mode of trans-
mission] of patients were obtained at the study
enrolment by well-trained research staff through
face-to-face interviews based upon a structured ques-
tionnaire. In addition to physical examination by two
research physicians, complete blood count (CBC),
platelet count, CD4 cell count and HIV viral load
(copies/ml) were measured. CD4 cell count was de-
termined by flow cytometric technique FACScan (BD
Biosciences, USA) and HIV viral load was measured
using a commercial kit (Amplicor HIV-1 Monitor
Test, Roche Molecular Systems Inc., USA). To ad-
dress the present research question, the remaining
freeze-stored plasma samples from our previous study
were retrospectively tested for hepatitis B surface
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antigen (HBsAg), anti-hepatitis B core antibody (anti-
HBcAb) and antibody to hepatitis C virus (anti-HCV)
were retrospectively tested using commercially kits :
Cobas Core HBsAg II EIA, Anti-HBc EIA, and
ETI-AB-HCVK-4 (DiaSorin S.p.A., Italy). HBsAg
positivity and anti-HCV positivity were determined
to define HBV and HCV co-infection, respectively.
Cohort patient survival was assessed on 15 October
2004. Survival status for each patient was ascertained
by hospital records, death certificates, mailing letters,
and contacting families or relatives. Causes of death
in HIV/hepatitis co-infected patients were investi-
gated by reviewing hospital records.
Analysis
In survival analysis, patients who started HAART
before 15 October 2004 were regarded as censored
on the date of starting HAART. Kaplan–Meier
survival analysis was performed to estimate survival
in relation to the existence of HIV/HBV or HCV
co-infection. HBV co-infected patients were divided
into two subgroups according to the existence of
anti-HBcAb. We used the log-rank test to compare
Kaplan–Meier curves. Additionally, Cox’s propor-
tional hazard model was conducted to evaluate the
influence of HBV or HCV co-infection on survival
adjusted by several factors. In multivariate models,
other than hepatitis co-infection status and existence
of anti-HBcAb, we included all variables with P<0.1
in univariate analysis. Results were presented as
hazard ratios (HRs) with 95% confidence intervals
(CIs). The proportional hazard assumption was
explored using Nelson–Aalen plots and the likelihood
ratio test. Statistical analyses were conducted using
SPSS version 17.0 (SPSS Inc., USA) and Stata version
11.0 (StataCorp., USA).
Ethical approval
This study was conducted as part of the Lampang
HIV Cohort Phase I and Lampang & Phayao HIV
Cohort Phase II, which were approved by Research




Seven hundred and fifty-five patients (over 95% of
patients who attended the clinic during the targeted
period) were enrolled in the study. Of 755 HIV-
infected persons, 55 patients were excluded (32
patients had received HAART in private clinic or
other clinical trial before recruitment, 22 patients had
incomplete testing for hepatitis co-infection, and four
patients had HBV/HCV dual co-infection). Baseline
characteristics of patients are summarized in Table 1.
Male:female ratio was 0.75. Median age at enrolment
was 33 years (95% CI 29–37), and 21.8% had re-
ceived mono or dual ART. The major transmission
route was heterosexual (96.7%) and half of partici-
pants were asymptomatic. The CD4 cell count was
>200 cells/ml in 299 (41.5%) patients and<50 cells/ml
in 261 (36.3%) patients. The prevalence of HBV and
HCV co-infection was 11.9% and 3.3%, respectively.
Of 700 patients, 681 (97.3%) had both HBsAg and
anti-HBcAb status. HCV co-infection was strongly
associated with IDU (P<0.001). All IDU cases were
co-infected with HCV. The baseline CD4 cell count
was significantly lower in HBV vs. HCV co-infected
patients whereas there was no difference between
these patient groups in their baseline viral load.
Patients with HBV co-infection were more likely
to have AIDS symptoms compared to HIV mono-
infected patients (P=0.02). Platelet counts were
lowest in HCV co-infected individuals followed by
HBV co-infected patients (P=0.03). Table 2 shows
the status of HBsAg and anti-HBcAb. Of 86 HBV
co-infected patients, 78 (90.7%) had anti-HBcAb.
Interestingly, eight (9.3%) patients did not have
anti-HBcAb despite being HBsAg positive.
Impact of chronic hepatitis infection on all-cause
mortality
Complete follow-up data were available for 694
(99.1%) patients in the evaluated cohort. Total
follow-up time was 1166.7 person-years of obser-
vation (pyo) with a median patient follow-up of 588
days [interquartile range (IQR), 317–967]. During the
observation period, 258 (36.9%) patients died, re-
sulting in a mortality rate of 22.1/100 pyo (95% CI
16.7–27.8). When stratified according to baseline
CD4 cell count, mortality was 64.6/100 pyo (95%
CI 59.1–70.9) in patients with CD4 <50 cells/ml com-
pared to 22.9/100 pyo (95%CI 16.3–29.7) in the group
with CD4 <50–200 cells/ml and 5.17/100 pyo (95%
CI 2.57–7.63) in patients with CD4 >200 cells/ml.
When stratified with baseline clinical status, mortality
was 8.71/100 pyo (95% CI 5.76–11.6) in asympto-
matic patients, 27.5/100 pyo (95% CI 19.6–34.4) in
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symptomatic but non-AIDS patients and 60.6/100
pyo (95% CI 54.4–66.7) in symptomatic AIDS
patients. Kaplan–Meier survival analysis (Fig. 1)
revealed that HBV co-infection significantly increased
mortality (P<0.001, log-rank test). HCV co-infection
also tended to increase mortality, but the statistical
significance was marginal. The curves for HIV/HBV
and HCV/HIV co-infection converge at about 500
days. The likelihood ratio test for interaction by time
band with a cut-point at 500 days revealed a P value
of 0.2, confirming lack of evidence for a relevant
violation of the proportional hazard assumption,
allowing the use of Cox regression analysis. The in-
fluence of hepatitis co-infection on survival analysed
by the Cox proportional hazard model is presented in
Table 3a. In univariate analysis, factors associated
with death were male gender, previous ART treat-
ment, clinical symptom at enrolment, baseline CD4
cell count, baseline viral load, HBV co-infection and
existence of anti-HBcAb. Patients with a low platelet
count (<150 000) were more likely to die than those
with a higher platelet count. In multivariate analysis,
there was no significant association between platelet
count and death. HCV co-infection showed a
tendency towards association with decreased survival.
HBV serology and mortality
Survival estimates focused on HBV serology interest-
ingly showed that HBV co-infected individuals with-
out anti-HBcAb had the poorest survival compared








Age (median, IQR)* 33 (29–37) 32 (29–35) 30 (26–34)
Male gender (%) 244 (41.1) 42 (50.6) 14 (50.9)
Mode of transmission (%)*#$
Heterosexual 583 (98.1) 79 (95.2) 15 (65.2)
Homosexual 6 (1.0) 1 (1.2) 1 (4.3)
IDU 0 (0.0) 0 (0.0) 5 (21.7)
Others or multiple 5 (0.8) 2 (2.4) 2 (8.6)
Unknown 0 (0.0) 1 (1.2) 0 (0.0)
Previous ART (%)· 129 (21.7) 17 (20.5) 4 (17.4)
Clinical status (%)#||
Asymptomatic 312 (52.5) 32 (38.6) 8 (34.8)
Non-AIDS symptomatic 115 (19.4) 15 (18.1) 7 (30.4)
AIDS symptomatic 167 (28.1) 36 (43.4) 8 (34.8)
Baseline CD4 cell count (cells/ml)
(median, IQR)*#$
150 (22–351) 64 (19–219) 334 (31–459)
Baseline vial load (copies/ml)
(median, IQR)
157431 (34891–446396) 169773 (69806–437116) 112334 (21415–515515)
Baseline platelet count (median, IQR)# 261000 (215000–319000) 237000 (191000–300000) 213000 (170000–328000)
IQR, Interquartile range ; IDU, injecting drug user ; ART, antiretroviral therapy; AIDS, acquired immunodeficiency syn-
drome.
* P<0.05, HIV mono-infection vs. HCV co-infection.
# P<0.05, HIV mono-infection vs. HBV co-infection.
$ P<0.05, HBV co-infection vs. HCV co-infection.
· Experience with antiretroviral therapy is limited to monotherapy or dual therapy.
|| Definition of AIDS according to the National guidelines for the clinical management of HIV infection in children and
adults, 6th edn. Thailand: Ministry of Public Health, 2000.
Other than *, #, $ there were not any significant differences between the groups.
Table 2. Status of HBsAg and anti-HBcAb
anti-HBcAb(+) anti-HBcAb(–) Total
HBsAg(+) 78 8 86
HBsAg(–) 318 277 595
Total 396 285 681
HBsAg, Hepatitis B surface antigen; anti-HBcAb, anti-
hepatitis B core antibody.
Both HBsAg and anti-HBcAb status data were available for
681 patients.
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to HIV mono-infected or HBV co-infected patients
with anti-HBcAb (P<0.0001 by log-rank test, Fig. 2).
In multivariate analysis (Table 3b), in addition to
symptomatic AIDS and low CD4 cell count, HBV co-
infection without anti-HbcAb was a strong risk factor
for death (adjusted HR 6.34, 95% CI 3.99–10.3).
Cause of death in hepatitis co-infected patients
Although primary causes of death were unknown for
nine out of 56 HIV/hepatitis co-infected patients, the
majority of deaths (46/56, 82.1%) were attributed to
AIDS-related diseases. No patients were diagnosed
with liver failure before death except for one patient
who was hospitalized for 6 days due to newly diag-
nosed cirrhosis with portal hypertension. This patient
was lost to follow-up after discharge with a CD4 cell
count of 22 cells/ml and died 3 months later.
DISCUSSION
In the present study with a substantial sample size,
we have clearly demonstrated that HBV co-infection
significantly increased all-cause mortality of HAART-
naive HIV patients. It was only after the advent
of HAART substantially increased life expectancy
of HIV-infected individuals that the importance of
liver-related death due to hepatitis co-infection was
highlighted. Our data indicate that the influence
of hepatitis co-infection on the natural history of
HAART-naive HIV patients should not be ignored.
We also discovered an increased mortality of HCV
co-infected patients compared to HIV mono-infected
patients. The results of multivariate analysis showed
only a trend, but this is probably due to the small
number of HCV co-infection in this study.
There are some limitations of the present study.
First, the lack of data on HBV DNA and HCV RNA
viral load is a limitation. Patients spontaneously clear
HCV infection after acquisition. The absence of HCV
viraemia in anti-HCV-positive patients might explain
why HCV co-infection did not show the strong
association with death. Second, cause of death was
determined only by reviewing medical charts while
the information of survival status was ascertained by
contacting families and relatives in addition to re-
viewing hospital records. It is possible that cause of
death might have been misclassified in some cases.
However, we focused on all-cause mortality and these
limitations do not alter the main results of the study.
To our knowledge, this is the first study from a
resource-limited country to address the adverse influ-
ence of hepatitis co-infection on survival in HAART-
naive HIV patients. We also found a higher mortality
rate in this Thai population compared to white























Fig. 1. Kaplan–Meier survival probability estimate of co-infected and mono-infected individuals showing that HBV
co-infection significantly increased mortality.
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implies that the high prevalence of hepatitis co-
infection is at least partially responsible for the high
mortality observed in HIV-infected individuals in
resource-limited countries. Several studies have in-
vestigated the influence of hepatitis co-infection on
the natural course of HIV infection but these studies
often include patients receiving HAART and show
conflicting findings [12–14, 16, 17, 23]. One of the
reasons for this discrepancy appears to be the sample
sizes in previous studies [16, 23]. In addition, none
of the previous studies has analysed the association
between HIV and HBV or HCV co-infection after
adjusting for clinical status, viral load, and CD4 cell
count in a cohort not receiving HAART with sub-
stantial sample size.
Our investigation of hospital records did not iden-
tify any patients with liver failure, with one exception.
We might have undiagnosed hepatocellular carcinoma
in some patients. However, we believe that the
majority of chronic HBV or HCV co-infected HIV
patients died from AIDS-defined illness rather than
liver failure, since they all had significant oppor-
tunistic infections with a very low CD4 cell count.
These results suggest that hepatitis co-infection ac-
celerates the natural course of HIV infection itself. An
in vitro study has demonstrated that HBV-X protein
super-induces ongoing HIV replication and HIV-1
long-terminal repeat transcription [24]. However, ac-
cording to our results, HBV co-infection increased the
mortality independent of HIV viral load. Thus, the
increased HIV viral load per se does not fully explain
the higher mortality in HBV co-infected patients.
We also considered the possibility that the higher
mortality in HBV co-infected patients might have
been due to confounding factors. However, our mul-
tivariate analysis demonstrated that the association
Table 3 (a). Influence of HBV or HCV co-infection on survival
Variables HR (95% CI) P value aHR (95% CI) P value
Male sex 2.59 (2.02–3.33) <0.001 1.23 (0.94–1.60) 0.14
Age <30 years* 0.79 (0.61–1.01) 0.06 0.81 (0.63–1.05) 0.11
Previous ART# 0.67 (0.49–0.92) 0.01 1.16 (0.84–1.61) 0.37
Transmission mode
IDU Ref. — — —
Homosexual 0.36 (0.05–2.58) 0.31 — —
Heterosexual 0.68 (0.17–2.72) 0.58 — —
Others 1.12 (0.21–6.13) 0.89 — —
Clinical symptom*$
Asymptomatic Ref. — Ref. —
Symptomatic, non-AIDS 3.06 (2.16–4.33) <0.001 1.42 (0.96–2.08) 0.08
AIDS, symptomatic 6.65 (4.93–8.98) <0.001 2.05 (1.44–2.93) <0.001
Baseline CD4 cell count# (cells/ml)
o200 Ref. — Ref. —
50–199 4.46 (2.91–6.84) <0.001 2.98 (1.85–4.79) <0.001
<50 12.7 (8.72–18.6) <0.001 6.44 (4.04–10.3) <0.001
Baseline viral load (copies/ml)
<10000 Ref. — Ref. —
10000–49999 2.44 (1.04–5.75) 0.04 1.20 (0.48–3.01) 0.70
50000–99999 3.30 (1.39–7.85) 0.007 1.67 (0.70–4.00) 0.25
o100000 8.79 (4.13–18.7) <0.001 2.19 (0.96–5.00) 0.06
Baseline platelet count
<150000 1.52 (1.00–2.29) 0.05 1.16 (0.76–1.78) 0.50
HBV co-infection 2.05 (1.49–2.82) <0.001 1.81 (1.30–2.53) <0.001
HCV co-infection 1.26 (0.67–2.38) 0.47 1.90 (0.98–3.69) 0.06
HR, Hazard ratio ; CI, confidence interval ; aHR, adjusted hazard ratio ; ART, antiretroviral therapy ; IDU, injecting drug
user ; AIDS, acquired immunodeficiency syndrome.
* At the time of enrolment.
# Experience with antiretroviral therapy is limited to monotherapy or dual therapy.
$ Definition of AIDS according to the National guidelines for the clinical management of HIV infection in children and
adults, 6th edn. Thailand: Ministry of Public Health, 2000.
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with HBV co-infection was independent of age,
gender, transmission route, clinical symptoms and
immunological status such as CD4 cell count.
Nevertheless, as with most multivariate regression
models, residual confounding cannot be fully ruled
out. We also analysed some behavioural factors
like excessive alcohol consumption. However, we
did not find any significant association with HBV
co-infection.
It is striking that HBV co-infected patients without
anti-HBcAb had the poorest prognosis. Even after
adjustment for demographic and clinical factors,
the impact on death remained substantially high.
Avettand-Fenoel et al. suggested three circumstances
leading to failure to elicit anti-HBcAb during HBV
infection [25]. Our patients may fit two of these
circumstances. First, the majority of HBV patients in
developing countries were vertically infected. It is
hypothesized that infants born to HBeAg-positive
carrier mothers may result in the lack of anti-HBcAb
production as they have helper T-cell tolerance to
HBV core Ag and HBeAg induced by transplacental
maternal HBVAg. Another reason for lack of anti-
HBcAb production is due to immunocompromised
condition like uncontrolled HIV infection. If the
former circumstance is true, these patients should be
HBVe Ag-positive but such data is not available in
this study. Clinical implication of the absence of anti-
HBcAb during chronic HBV infection remain largely
unknown except that it is not linked to severe hepatic
disease course [26] although its impact on HIV pro-
gression has never been reported. We found that the
frequency of HBV patients without anti-HBcAb
is not uncommon in our HIV-infected population.
Together with the poor prognosis, our observation
suggests that more attention should be given to this
group. However, the results should be interpreted
with caution because of the small number of HBV
patients without anti-HBcAb.
After the initiation of HAART, in both wealthy
and resource-limited countries, the proportion of
liver-related mortality increased in hepatitis and HIV
co-infected patients [27–30]. Unfortunately, adequate
treatment for chronic hepatitis is not available in
resource-limited countries. A tenofovir-based first-
line regimen is now recommended by WHO and is
being adopted in many countries. However, the price
of tenofovir needs to fall to allow more widespread
access to this drug. Currently, the prevailing regimen
for chronic hepatitis infection includes lamivudine
alone in the most resource-limited countries. Thus,
most HIV patients with HBV co-infection are in-
evitably receiving lamivudine monotherapy for HBV
infection. The choice of antiretrovirals for such
patients should include at least two drugs effective
against HBV such as tenofovir. Last, screening
for hepatitis co-infection at the same time as HIV






















Fig. 2. Kaplan–Meier survival probability estimate showing that HBV co-infected individuals without anti-HBcAb had the
poorest survival compared to HIV mono-infected or HBV co-infected patients with anti-HBcAb.
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In summary, whereas HCV co-infection showed
marginal association with the survival, HBV co-
infection, especially without anti-HBcAb, increased
the all-cause mortality in HAART-naive HIV pa-
tients in resource-limited countries. In this setting,
clinicians and healthcare providers should prioritize
HIV/chronic hepatitis co-infected individuals.
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Table 3 (b). Impact of HBs Ag and anti-HBc Ab status on survival
Variables HR (95% CI) P value aHR (95% CI) P value
Male sex 2.59 (2.02–3.33) <0.001 1.23 (0.96–1.63) 0.11
Age <35 years* 0.79 (0.61–1.01) 0.06 0.79 (0.61–1.02) 0.08
Previous ART# 0.67 (0.49–0.92) 0.01 1.10 (0.79–1.53) 0.59
Transmission mode
IDU Ref. — — —
Homosexual 0.36 (0.05–2.58) 0.31 — —
Heterosexual 0.68 (0.17–2.72) 0.58 — —
Others 1.12 (0.21–6.13) 0.89 — —
Clinical symptom*$
Asymptomatic Ref. Ref. —
Symptomatic, non AIDS 3.06 (2.16–4.33) <0.001 1.47 (1.10–2.15) 0.05
AIDS, symptomatic 6.65 (4.93–8.98) <0.001 2.03 (1.42–2.90) <0.001
Baseline CD4 cell count# (cells/ml)
o200 Ref. — Ref. —
50–199 4.46 (2.91–6.84) <0.001 2.03 (1.42–2.90) <0.001
<50 12.7 (8.72–18.6) <0.001 6.34 (3.99–10.3) <0.001
Baseline viral load (copies/ml)
<10000 Ref. — Ref. —
10000–49999 2.44 (1.04–5.75) 0.04 1.73 (0.72–4.13) 0.22
50000–99999 3.30 (1.39–7.85) 0.007 1.17 (0.47–2.93) 0.74
o100000 8.79 (4.13–18.7) <0.001 2.09 (0.91–4.78) 0.08
Baseline platelet count
<150000 1.52 (1.00–2.29) 0.05 1.28 (0.84–1.94) 0.25
HBV serology
HBsAg(–) Ref. — Ref. —
HBsAg(+)anti-HBcAb(–) — — 6.34 (3.99–10.3) <0.001
HBsAg(+) anti-HBcAb(+) — — 1.62 (1.14–2.29) 0.007
IQR, Interquartile range ; ART, antiretroviral therapy; AIDS, acquired immunodeficiency syndrome; HR, hazard ratio ;
aHR, adjusted hazard ratio ; CI, confidence interval ; HBsAg, hepatitis B surface antigen; anti-HBcAb, anti-hepatitis B core
antibody.
* At the time of enrolment.
# Experience with antiretroviral therapy is limited to mono- or dual-therapy.
$ Definition of AIDS according to the National guidelines for the clinical management of HIV infection in children and
adults, 6th edn. Thailand: Ministry of Public Health, 2000.
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